ALK and acinar cell carcinoma: At diagnosis, there were 83 (72.8%) stage I/II patients, 76 (66.7%) with acinar adenocarcinoma, and a total of 48 (42.1%) cases and 14 (12.3%) patients with EGFR mutations and other mutations, including KRAS and ALK, respectively.